Pharmala Biotech Holdings Inc
Canadian Securities Exchange:MDMAView on Grey Market

  • LAST PRICE
    0.1700
  • TODAY'S CHANGE (%)
    -0.0050 (-2.8571%)
  • Bid / Lots
    0.1650/ 18
  • Ask / Lots
    0.1700/ 17
  • Open / Previous Close
    0.1750 / 0.1750
  • Day Range
    0.1650
    0.1800
  • 52 Week Range
    0.0650
    0.3500
  • Volume
    102,414

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 21, 2024

  • Oct 8, 2024

      Show headlines and story abstract

    • 8:55AM ET on Tuesday Oct 08, 2024 by Dow Jones
      Companies Mentioned: MDMA

      PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo(TM) MDMA

      TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo(TM) MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a proposed clinical trial at the University of Texas, San Antonio. Pursuant to a submitted grant funding application by the principals, the contract envisions the creation of a new dosage form for LaNeo(TM) MDMA, which will subsequently be tested in an investigator-initiated human clinical trial.

  • Oct 2, 2024

Peers Headlines